
    
      PRIMARY OBJECTIVES:

      I. Determine the clinical benefit of treatment with immunoembolization (IEMBO) in combination
      with ipilimumab and nivolumab.

      SECONDARY OBJECTIVES:

      I. Determine all treatment and immune related toxicities. II. Determine progression free
      survival. III. Determine overall survival.
    
  